(MAZE) Maze Therapeutics, Common - Ratings and Ratios

Exchange: US • Country: United States • Currency: USD • Type: Common Stock • ISIN: (N/A)

MZE829, MZE782, MZE001, Renal, Cardiovascular

Stock: Pharmaceuticals
Age 1y
MCap 1,916m
Avg Vol 325K (12.9M USD)
Beta 0.877
Volatility 60.91%

EPS (Earnings per Share)

EPS (Earnings per Share) of MAZE over the last years for every Quarter: "2022-12": null, "2023-09": null, "2023-12": null, "2024-03": null, "2024-06": null, "2024-09": null, "2024-12": -18.32, "2025-03": -1.15, "2025-06": -0.77, "2025-09": -0.66,
EPS CAGR: 0.00%
EPS Trend: 83.6%
Qual. Beats: 0

Revenue

Revenue of MAZE over the last years for every Quarter: 2022-12: null, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 165, 2024-09: 2.5, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0,
Rev. CAGR: 0.00%
Rev. Trend: -13.6%
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 60.9%
Value at Risk 5%th 92.6%
Relative Tail Risk -7.58%
Reward TTM
Sharpe Ratio 1.47
Alpha 162.70
CAGR/Max DD 3.56
Character TTM
Hurst Exponent 0.394
Beta 0.877
Beta Downside 0.581
Drawdowns 3y
Max DD 52.69%
Mean DD 17.33%
Median DD 16.22%

Description: MAZE Maze Therapeutics, Common December 26, 2025

Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharma focused on orally administered small-molecule precision medicines targeting renal, cardiovascular, metabolic disorders and obesity in the U.S. Its lead pipeline comprises MZE829, a Phase II APOL1 inhibitor for APOL1-associated kidney disease, and MZE782, a Phase I SLC6A19 inhibitor for chronic kidney disease, plus MZE001 for Pompe disease. The company was incorporated in 2017 (formerly Modulus Therapeutics) and is headquartered in South San Francisco.

Key external drivers: (1) The global chronic kidney disease market is projected to exceed $100 billion by 2028, providing a sizable addressable pool for MZE829 and MZE782. (2) APOL1 risk variants affect roughly 13 % of individuals of African ancestry, translating to an estimated 1–2 million U.S. patients with heightened CKD risk-a niche but high-unmet-need segment. (3) Biotech R&D efficiency remains low; historically only ~10 % of Phase II programs progress to approval, underscoring the importance of clear mechanistic data and biomarker-driven trial designs for Maze’s success.

For a data-driven deep-dive into MAZE’s valuation assumptions and comparable peer metrics, you may find ValueRay’s analytical toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-126.1m TTM) > 0 and > 6% of Revenue (6% = 10.1m TTM)
FCFTA -0.26 (>2.0%) and ΔFCFTA -65.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 220.4% (prev 81.43%; Δ 139.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.25 (>3.0%) and CFO -106.7m > Net Income -126.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 17.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (45.8m) change vs 12m ago 4.57% (target <= -2.0% for YES)
Gross Margin 98.78% (prev 98.38%; Δ 0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 54.51% (prev 87.02%; Δ -32.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -51.83 (EBITDA TTM -126.3m / Interest Expense TTM -2.49m) >= 6 (WARN >= 3)

Altman Z'' -11.80

(A) 0.87 = (Total Current Assets 391.3m - Total Current Liabilities 22.1m) / Total Assets 422.1m
(B) -1.08 = Retained Earnings (Balance) -455.0m / Total Assets 422.1m
warn (B) unusual magnitude: -1.08 — check mapping/units
(C) -0.42 = EBIT TTM -128.9m / Avg Total Assets 307.3m
(D) -10.67 = Book Value of Equity -454.9m / Total Liabilities 42.6m
Total Rating: -11.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 24.57

1. Piotroski 0.50pt
2. FCF Yield -6.94%
3. FCF Margin -64.49%
4. Debt/Equity 0.06
5. Debt/Ebitda 2.32
6. ROIC - WACC (= -90.03)%
7. RoE -44.62%
8. Rev. Trend -13.63%
9. EPS Trend 83.60%

What is the price of MAZE shares?

As of January 21, 2026, the stock is trading at USD 44.34 with a total of 515,873 shares traded.
Over the past week, the price has changed by +7.13%, over one month by +5.62%, over three months by +49.04% and over the past year by +177.13%.

Is MAZE a buy, sell or hold?

Maze Therapeutics, Common has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MAZE.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MAZE price?

Issuer Target Up/Down from current
Wallstreet Target Price 47.3 6.7%
Analysts Target Price 47.3 6.7%
ValueRay Target Price 51.2 15.5%

MAZE Fundamental Data Overview January 17, 2026

P/S = 3.1363
P/B = 5.0486
Revenue TTM = 167.5m USD
EBIT TTM = -128.9m USD
EBITDA TTM = -126.3m USD
Long Term Debt = 24.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.76m USD (from shortTermDebt, last quarter)
Debt = 24.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -292.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.56b USD (1.92b + Debt 24.2m - CCE 383.9m)
Interest Coverage Ratio = -51.83 (Ebit TTM -128.9m / Interest Expense TTM -2.49m)
EV/FCF = -14.40x (Enterprise Value 1.56b / FCF TTM -108.0m)
FCF Yield = -6.94% (FCF TTM -108.0m / Enterprise Value 1.56b)
FCF Margin = -64.49% (FCF TTM -108.0m / Revenue TTM 167.5m)
Net Margin = -75.30% (Net Income TTM -126.1m / Revenue TTM 167.5m)
Gross Margin = 98.78% ((Revenue TTM 167.5m - Cost of Revenue TTM 2.04m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.69 (Enterprise Value 1.56b / Total Assets 422.1m)
Interest Expense / Debt = -10.28% (Interest Expense -2.49m / Debt 24.2m)
Taxrate = 2.19% (1.17m / 53.4m)
NOPAT = -126.1m (EBIT -128.9m * (1 - 2.19%)) [loss with tax shield]
Current Ratio = 17.70 (Total Current Assets 391.3m / Total Current Liabilities 22.1m)
Debt / Equity = 0.06 (Debt 24.2m / totalStockholderEquity, last quarter 379.4m)
Debt / EBITDA = 2.32 (negative EBITDA) (Net Debt -292.6m / EBITDA -126.3m)
Debt / FCF = 2.71 (negative FCF - burning cash) (Net Debt -292.6m / FCF TTM -108.0m)
Total Stockholder Equity = 282.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.05% (Net Income -126.1m / Total Assets 422.1m)
RoE = -44.62% (Net Income TTM -126.1m / Total Stockholder Equity 282.7m)
RoCE = -42.01% (EBIT -128.9m / Capital Employed (Equity 282.7m + L.T.Debt 24.2m))
RoIC = -81.00% (negative operating profit) (NOPAT -126.1m / Invested Capital 155.6m)
WACC = 9.04% (E(1.92b)/V(1.94b) * Re(9.15%) + (debt cost/tax rate unavailable))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.26%
Fair Price DCF = unknown (Cash Flow -108.0m)
EPS Correlation: 83.60 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: -13.63 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.78 | Chg30d=+0.008 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-3.16 | Chg30d=+0.034 | Revisions Net=+0 | Growth EPS=-2.9% | Growth Revenue=+0.0%

Additional Sources for MAZE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle